This is in agreement with recent studies by Sevelda et al. [32], who observed that the blockade of EGFR by gefitinib inhibited osteosarcoma cell proliferation independently from their EGFR expression levels in osteosarcoma cell lines. The gene discussed is EGFR; the disease is osteosarcoma.